Koninklijke Philips N.V.
Koninklijke Philips N.V. PHIA.AS Peers
See (PHIA.AS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHIA.AS | €20.29 | -1.50% | 19.2B | 78.04 | €0.26 | +4.19% |
| IBAB.BR | €11.48 | -0.69% | 336.3M | 37.03 | €0.31 | +2.09% |
| EAPI.PA | €3.22 | +4.07% | 306.8M | -2.33 | -€1.38 | N/A |
| GBT.PA | €22.50 | +0.67% | 283.6M | 17.72 | €1.27 | N/A |
| ALERS.PA | €25.25 | +0.00% | 252.6M | 64.74 | €0.39 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| SEQUA.BR | €1.53 | +8.51% | 87.5M | -1.25 | -€1.22 | N/A |
| AFME.PA | €1.36 | +2.64% | 51.4M | -3.32 | -€0.41 | N/A |
| ALMDT.PA | €2.38 | +3.03% | 46M | -1.74 | -€1.37 | N/A |
| ALCAR.PA | €0.62 | +79.19% | 36.5M | -0.54 | -€1.15 | N/A |
Stock Comparison
PHIA.AS vs IBAB.BR Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, IBAB.BR has a market cap of 336.3M. Regarding current trading prices, PHIA.AS is priced at €20.29, while IBAB.BR trades at €11.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas IBAB.BR's P/E ratio is 37.03. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to IBAB.BR's ROE of +0.09%. Regarding short-term risk, PHIA.AS is less volatile compared to IBAB.BR. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs EAPI.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, EAPI.PA has a market cap of 306.8M. Regarding current trading prices, PHIA.AS is priced at €20.29, while EAPI.PA trades at €3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas EAPI.PA's P/E ratio is -2.33. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to EAPI.PA's ROE of -0.14%. Regarding short-term risk, PHIA.AS is less volatile compared to EAPI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs GBT.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, GBT.PA has a market cap of 283.6M. Regarding current trading prices, PHIA.AS is priced at €20.29, while GBT.PA trades at €22.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas GBT.PA's P/E ratio is 17.72. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to GBT.PA's ROE of +0.04%. Regarding short-term risk, PHIA.AS is less volatile compared to GBT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALERS.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALERS.PA has a market cap of 252.6M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALERS.PA trades at €25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALERS.PA's P/E ratio is 64.74. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALERS.PA's ROE of +0.02%. Regarding short-term risk, PHIA.AS is more volatile compared to ALERS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALCOR.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, PHIA.AS is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs SEQUA.BR Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, SEQUA.BR has a market cap of 87.5M. Regarding current trading prices, PHIA.AS is priced at €20.29, while SEQUA.BR trades at €1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas SEQUA.BR's P/E ratio is -1.25. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to SEQUA.BR's ROE of +2.05%. Regarding short-term risk, PHIA.AS is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs AFME.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, AFME.PA has a market cap of 51.4M. Regarding current trading prices, PHIA.AS is priced at €20.29, while AFME.PA trades at €1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas AFME.PA's P/E ratio is -3.32. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to AFME.PA's ROE of -0.51%. Regarding short-term risk, PHIA.AS is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALMDT.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALMDT.PA has a market cap of 46M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALMDT.PA trades at €2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALMDT.PA's P/E ratio is -1.74. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALMDT.PA's ROE of +0.90%. Regarding short-term risk, PHIA.AS is less volatile compared to ALMDT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALCAR.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALCAR.PA has a market cap of 36.5M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALCAR.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALCAR.PA's P/E ratio is -0.54. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALCAR.PA's ROE of +1.40%. Regarding short-term risk, PHIA.AS is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALNOV.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALNOV.PA has a market cap of 33.9M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALNOV.PA trades at €0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALNOV.PA's P/E ratio is -0.75. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALNOV.PA's ROE of -0.23%. Regarding short-term risk, PHIA.AS is less volatile compared to ALNOV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs MKEA.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, PHIA.AS is priced at €20.29, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, PHIA.AS is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALDMS.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALDMS.PA has a market cap of 26.3M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALDMS.PA trades at €1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALDMS.PA's P/E ratio is -10.12. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALDMS.PA's ROE of -0.25%. Regarding short-term risk, PHIA.AS is less volatile compared to ALDMS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALIKO.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALIKO.PA has a market cap of 21.2M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALIKO.PA trades at €1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALIKO.PA's P/E ratio is -5.85. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIKO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALTER.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, PHIA.AS is less volatile compared to ALTER.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALTHE.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALTHE.PA has a market cap of 15.1M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALTHE.PA trades at €0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALTHE.PA's P/E ratio is -2.71. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALTHE.PA's ROE of -1.29%. Regarding short-term risk, PHIA.AS is more volatile compared to ALTHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALEMG.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALEMG.PA has a market cap of 12.9M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALEMG.PA trades at €4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALEMG.PA's P/E ratio is 30.13. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALEMG.PA's ROE of +0.94%. Regarding short-term risk, PHIA.AS is less volatile compared to ALEMG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALIMP.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALIMP.PA has a market cap of 12.7M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALIMP.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALIMP.PA's P/E ratio is -2.55. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALIMP.PA's ROE of -2.06%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALBLU.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALBLU.PA has a market cap of 6.6M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALBLU.PA trades at €0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALBLU.PA's P/E ratio is -5.40. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALBLU.PA's ROE of -0.61%. Regarding short-term risk, PHIA.AS is less volatile compared to ALBLU.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs ALSGD.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, ALSGD.PA has a market cap of 6.3M. Regarding current trading prices, PHIA.AS is priced at €20.29, while ALSGD.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas ALSGD.PA's P/E ratio is -1.67. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALSGD.PA's ROE of -0.59%. Regarding short-term risk, PHIA.AS is less volatile compared to ALSGD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.
PHIA.AS vs DGM.PA Comparison
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 19.2B. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, PHIA.AS is priced at €20.29, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 78.04, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to DGM.PA's ROE of -0.35%. Regarding short-term risk, PHIA.AS is less volatile compared to DGM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.